Venture Center
Incubation & Mentoring Pre-Incubation Virtual Resident
Funding Grants Seed Investment Fellowship CSR Funding Database
Services Scientific services & Facilities Prototyping Facility & Support Analytical & Measurement Support Advisory Consulting Infrastructural support services Regulatory Services
Programs Investor Readiness Program BFI BIOME MSME DEIA Catalyst Lab2Mkt: Spinouts from academic organizations Early Translation Accelerator MeiTY SAMRIDH Bioincubation Social Innovation BRBC
Our Startups Startup directory Success Stories
About us History & Milestones Life at VC Awards & Recognition Corporate Governance Our People
Resources Annual Reports AiM Prime Playbook Candid Venture Center Library Technology Database
Projects MSME IP Facilitation Center BIRAC BioNest NBM – CBA Bajaj Auto CSR — Med Tech Clean Room NIDHI-CoE BIRAC-BRBC NBM-RTTO MEITY-SAMRIDH IBPL — Solar Farm
Careers Events Impact News Blog Support us Contact

17th BioPune Series talk: Development and Translation of Cell-Targeted Systemic Nanomedicines

Venture Center is happy to announce the 17th Talk on BioPune Seminar Series
 
Development and Translation of Cell-Targeted Systemic Nanomedicines
Organized by: BioIncubator and TechEx.in @ Venture Center, Pune | Supported by NBM and BIRAC

Monday, 02 December, 2024| Time: 12:30 PM - 1:30 PM | HYBRID: In person at Lecture Theatre @ Venture Center and Online via Zoom

Highlights of the talk: 
  • Dr. Kannan's team has developed dendrimer-drug conjugates with significant potential for neurological, ocular, and cardiometabolic disorders, achieving groundbreaking clinical outcomes for severe COVID-19, AMD, and diabetic retinopathy
  • Through extensive validation in animal models and clinical trials, the team’s innovations have spurred multiple start-ups and translational efforts in the US and India
  • The talk will highlight the application of this approach in treating inflammatory, obesity, retinal, and brain disorders, and discuss recent advancements in developing innovative applications for antibody delivery
  • It will also focus on the journey of transforming innovative ideas into successful start-ups, driving translational efforts and first-generation therapies in both India and the US.
About our speaker:  Kannan Rangaramanujam, Ph.D. (Arnall Patz Distinguished Professor of Ophthalmology, Center for Nanomedicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA)
  • Dr. Kannan Rangaramanujam is the Arnall Patz Distinguished Professor of Ophthalmology and Co-Director of Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins School of Medicine. 
  • He is a chemical engineer by training [PhD (Caltech);  BE(Hons.)(BITS, Pilani)]. His research interests are in the field of translational nanomedicine centered on novel approaches to target specific cells at the site of injury. 
  • His team has developed and extensively validated the hydroxyl dendrimer platform through Hopkins-wide collaborations in many animal models of ocular, brain disorders, pain, depression, and cancer. These have the opportunity to address long standing challenges in the field, and will lead to medicines that are easy to administer (e.g., oral pills for AMD and diabetic retinopathy), have minimal side effects, and affordable to large fractions of the world population. 
  • He is leading the translation of his research to the clinic, through start-ups and partnerships.  
  • He is the co-founder of Ashvattha Therapeutics Inc. and Samata Therapeutics ( more than $100M raised) – Johns Hopkins spinoffs that are translating some of his team’s patented dendrimer technologies to the clinic, with three products that have completed, or in Phase 2 trials. OP-101, a product developed from his group showed significant promise in Phase 2 trials for severe COVID-19. A subcutaneous, targeted therapy for wet AMD and diabetic retinopathy is undergoing Phase 2 trials. 
  • Dr. Rangaramanujam is an author of more than 150 patents (issued and pending, licensed), more than 150 peer-reviewed publications, and is supported by significant NIH and federal funding. 
  • He has won several recognitions, including fellowship of the American Institute of Medical and Biological Engineers (AIMBE), Controlled Release Society, and Distinguished Alumni Award from BITS (Pilani). 
  • He is on the editorial boards of Biomaterials, Advanced Drug Delivery Reviews, and Theranostics.
 
The talk is free & open to all, but registration is mandatory| Register at- https://tinyurl.com/dec-talk
 
Note for the event: 
  • Organizers reserve the right to accept or refuse or delay registrations so to optimize the composition of the group and hence maximize learning for all participants
  • Only registered participants will be allowed to participate in the event
  • Email invitations with links to participate at the event will be sent closer to the event
Event related queries: Manish Gore | +91-7410045657 | manish.gore@venturecenter.co.in